左西替利嗪、孟鲁司特联合卡介菌素对慢性荨麻疹的治疗效果及价值分析  

Therapeutic effect and value of levocetirizine,montelukast combined with bacillus Calmette-Guerin on chronic urticaria

作　　者：赵国亮 ZHAO Guo-liang(Department of Dermatology and Venereology,Chengwu County People's Hospital,Heze 274200,China)

机构地区：[1]成武县人民医院皮肤性病科,274200

出　　处：《中国实用医药》2023年第7期120-123,共4页China Practical Medicine

摘　　要：目的研究左西替利嗪、孟鲁司特联合卡介菌素对评慢分性荨麻疹的治疗效果及价值。方法200例慢性荨麻疹患者,随机分为观察组和对照组,每组100例。对照组实施孟鲁司特联合卡介菌素治疗,观察组在对照组的基础上采用左西替利嗪治疗。比较两组患者症状消失时间、治疗效果、不良反应发生情况(轻度皮肤刺激、恶心、呕吐)及治疗前后生活质量评分、实验室指标[白三烯B4(LTB4)、白细胞介素(IL-)4、IL-6]。结果观察组患者烦躁消失时间(16.25±1.12)d、瘙痒消失时间(14.21±1.22)d、风团消失时间(15.25±1.45)d均短于对照组的(24.52±1.78)、(21.52±1.02)、(27.52±1.85)d,差异均具有统计学意义(P<0.05)。观察组治疗总有效率95.00%高于对照组的80.00%,差异具有统计学意义(P<0.05)。治疗后,观察组患者躯体功能评分(95.25±1.20)分、心理功能评分(94.56±1.45)分、社会功能评分(95.25±1.45)分、物质生活评分(95.75±1.45)分均高于对照组的(79.25±1.58)、(79.25±1.52)、(78.25±1.14)、(81.25±1.45)分,差异均具有统计学意义(P<0.05)。观察组不良反应发生率3.00%低于对照组的32.00%,差异具有统计学意义(P<0.05)。治疗后,观察组患者LTB4(14.33±1.54)pg/ml、IL-4(39.65±1.24)pg/ml、IL-6(166.98±1.54)pg/ml均低于对照组的(30.61±1.68)、(50.65±1.22)、(186.82±1.37)pg/ml,差异均具有统计学意义(P<0.05)。结论左西替利嗪、孟鲁司特联合卡介菌素对慢性荨麻疹的治疗效果十分显著,且安全性高。Objective To study the therapeutic effect and value of levocetirizine,montelukast combined with bacillus Calmette-Guerin on chronic urticaria.Methods A total of 200 patients with chronic urticaria were randomly divided into an observation group and a control group,with 100 cases in each group.The control group was treated with montelukast and bacillus Calmette-Guerin,and the observation group was treated with levocetirizine on the basis of the control group.Both groups were compared in terms of disappearance time of symptoms,therapeutic effect,occurrence of adverse reactions(mild skin irritation,nausea,vomiting),quality of life score,and laboratory indexes[leukotriene B4(LTB4),interleukin(IL)-4,IL-6]before and after treatment.Results The observation group had irritability disappearance time of(16.25±1.12)d,pruritus disappearance time of(14.21±1.22)d,and wheal disappearance time of(15.25±1.45)d,which were shorter than those of(24.52±1.78),(21.52±1.02),and(27.52±1.85)d in the control group,and the differences were statistically significant(P<0.05).The total effective rate of treatment in the observation group was 95.00%,which was higher than that of 80.00% in the control group,and the difference was statistically significant(P<0.05).After treatment,the observation group had physical function score of(95.25±1.20)points,psychological function score of(94.56±1.45)points,social function score of(95.25±1.45)points,and material life score of(95.75±1.45)points,which were higher than those of(79.25±1.58),(79.25±1.52),(78.25±1.14),and(81.25±1.45)points in the control group,and the differences were all statistically significant(P<0.05).The incidence of adverse reactions in the observation group was 3.00%,which was lower than that of 32.00% in the control group,and the difference was statistically significant(P<0.05).After treatment,the observation group had LTB4 of(14.33±1.54)pg/ml,IL-4 of(39.65±1.24)pg/ml and IL-6 of(166.98±1.54)pg/ml,which were lower than those of(30.61±1.68),(50.65±1.22)and(186.82±1.37

关 键 词：左西替利嗪 孟鲁司特 卡介菌素 慢性荨麻疹 

分 类 号：R758.24[医药卫生—皮肤病学与性病学]